このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

LianBio マネジメント

マネジメント基準チェック /14

LianBio'sの CEO はAdam Stoneで、 Dec2023年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.016%を直接所有しており、その価値は$ 5.53K 。経営陣と取締役会の平均在任期間はそれぞれ0.5年と2.7年です。

主要情報

Adam Stone

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.02%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	2.8yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Adam Stone (44 yo)

less than a year

在職期間

US$62,073

報酬

Mr. Adam Leo Stone is Chief Investment Officer & Head of Research of Perceptive Advisors LLC. He joined the Perceptive Advisors LLC in 2006. He serves as CEO & Director at Perceptive Capital Solutions Corp...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Konstantin Poukalov	Founder & Executive Chairman	4.8yrs	US$62.07k	0.016% $ 5.5k
Adam Stone	Interim CEO & Director	less than a year	US$62.07k	0.016% $ 5.5k
Ehong Gu	Interim CFO	less than a year	データなし	0% $ 0
Ji Chen	Senior VP & General Counsel	no data	データなし	データなし
Brianne Jahn	Chief Business Officer	2.9yrs	US$2.69m	データなし
Levvy Lv Eng	Senior VP & Global Head of Development	no data	データなし	データなし

0.7yrs

平均在職期間

40yo

平均年齢

経験豊富な経営陣: LIAN.Yの経営陣は経験豊富とはみなされません ( 0.5年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Konstantin Poukalov	Founder & Executive Chairman	4.8yrs	US$62.07k	0.016% $ 5.5k
Adam Stone	Interim CEO & Director	4.8yrs	US$62.07k	0.016% $ 5.5k
Tassos Anastasios Gianakakos	Independent Director	4yrs	US$128.07k	0.34% $ 116.2k
Susan Silbermann	Independent Director	2.8yrs	US$121.44k	0.016% $ 5.5k
Neil Kumar	Director	4.8yrs	データなし	0% $ 0
Elliott Levy	Member of Scientific Advisory Board	2.3yrs	データなし	データなし
Mathias Hukkelhoven	Member of Scientific Advisory Board	2.3yrs	データなし	データなし
Wei Chen	Independent Director	2.3yrs	US$285.89k	0% $ 0
Zhao Yan	Member of Scientific Advisory Board	2.3yrs	データなし	データなし

2.8yrs

平均在職期間

54.5yo

平均年齢

経験豊富なボード: LIAN.Yの取締役会は経験豊富ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

LianBio マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

LianBio Intends to File Form 25 with SEC

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

Concentra Biosciences, LLC cancelled the acquisition of LianBio (NasdaqGM:LIAN) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

New major risk - Revenue and earnings growth

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Lianbio Announces Marketing Approval of CAMZYOS®? (Mavacamten) in Singapore

LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in the Macau Special Administrative Region (SAR) of China

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Price target decreased to US$8.23

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Price target increased to US$12.00

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Lianbio Completes Enrollment in Pivotal Phase 3 EXPLORER-CNTrial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

U.S. Food and Drug Administration Approves Camzyos (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Less than half of directors are independent

LianBio Announces Formation of Scientific Advisory Board

LianBio Appoints Wei Wei Chen to Board of Directors

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Lianbio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio Announces Approval of Infigratinib Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

No independent directors

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14